Search

Your search keyword '"Ming‐Yen Hsieh"' showing total 113 results

Search Constraints

Start Over You searched for: Author "Ming‐Yen Hsieh" Remove constraint Author: "Ming‐Yen Hsieh" Topic business.industry Remove constraint Topic: business.industry
113 results on '"Ming‐Yen Hsieh"'

Search Results

1. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)

2. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients

3. Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community‐based cohort study

4. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan

5. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis

6. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy

7. Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication

8. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients

9. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C

10. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents

11. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment

12. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan

13. Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis

14. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals

15. Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide

16. Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan-the Formosa-Like Group

17. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)

18. The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C

19. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients

20. Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients

21. Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C

22. The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection

23. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort

24. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals

25. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients

26. Disease severity and erythropoiesis in chronic hepatitis C

27. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection

28. A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan

29. Hepatitis D virus infections among injecting drug users with and without human immunodeficiency virus infection in Taiwan

30. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection

31. Anti-HIV seropositivity was related to HBsAg seropositivity among injecting drug users in Taiwan

32. MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication

33. Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection

34. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles

35. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection

36. Impact of Ribavirin on Early Viral Kinetics in Chronic Hepatitis C Patients Receiving Directly Acting Antivirals

37. Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma

38. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication

39. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection

40. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study

41. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin

42. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C

43. Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy

44. Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment

45. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C

46. Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients

47. Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma

48. Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C

49. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization

50. Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma

Catalog

Books, media, physical & digital resources